[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"sexual-dysfunction\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:sexual-dysfunction":28},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,32,0,25,[9,42,73,98,124,149,177,207,231,268,295,319,346,367,390,413,436,465,488,518,550,571,592,625,647],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100582808","aya-omgyes-sexual-health-study-100582808",false,"NCT06868121","AYA OMGYES Sexual Health Study","Assessing the Impact of a Web-based Educational Program on the Sexual Health Outcomes of Young Adult Female Cancer Survivors ~ A Pilot Trial","Inclusion Criteria:\n\n* Age 18 to 45 years\n* Diagnosis of cancer between the ages of 15 and 45\n* Female genitalia, regardless of gender\n* Diagnosed with sexual dysfunction\n* Complete Remission and at least two months from a major treatment\n* Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial\n* Ability to participate in study modules and to respond to surveys\n* Ability to understand and the willingness to sign a written informed consent document\n\nExclusion Criteria:\n\n* Patients receiving other investigational agents\n* Patients expected to be neutropenic or have a significantly high infection risk that would exclude them from vaginal penetration\n* Patients who are unable complete the study intervention or surveys","FEMALE","18 Years","45 Years",{"count":21,"type":22},30,"ESTIMATED","INTERVENTIONAL",[25],"NA","The purpose of this study is to assess the impact of the web-based intervention OMGYES.com on sexual dysfunction in young adult (YA) female-bodied cancer survivors. This pilot trial seeks to evaluate the intervention's:\n\n* feasibility\n* acceptability\n* appropriateness.\n\nResearchers will utilize an active observation period to compare outcomes between those receiving the intervention immediately and those who haven't\n\nParticipants will:\n\n* Complete online modules at home\n* Visit the clinic every 5 weeks for questionnaires",[28],"Sexual Dysfunction","RECRUITING","2026-06-03",{"date":32,"type":33},"2026-06-05","ACTUAL",{"date":35,"type":33},"2025-01-16",{"date":37,"type":22},"2026-11-01",{"name":39,"class":40},"University of Chicago","OTHER",1,{"id":43,"slug":44,"hasResults":12,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":48,"eligibilityCriteria":49,"healthyVolunteers":12,"sex":50,"minAge":18,"maxAge":51,"enrollmentInfo":52,"targetDuration":4,"studyType":23,"phases":54,"briefSummary":55,"conditions":56,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":72},"100546486","internet-based-interventions-for-cardiac-arrest-survivors-100546486","NCT06395558","intErnet-based iNterventions FOR Cardiac arrEst suRvivors","Internet-Based Interventions for Cardiac Arrest Survivors","ENFORCER","Inclusion Criteria:\n\n* Hospital discharge after out-of-hospital cardiac arrest with Cerebral Performance Category 1 or 2\n* Informed consent for participation in the study\n* Native Italian speaker or adequate understanding of the Italian language\n* Adequate ability to use the web to guarantee access to the contents\n\nExclusion Criteria:\n\n* Previous cognitive dysfunction\n* Previous psychiatric disease\n* Previous episode of out-of-hospital cardiac arrest","ALL","80 Years",{"count":53,"type":22},106,[25],"This randomized clinical trial will test whether an internet-based lifestyle intervention administered through a web app can foster Health Related Quality of Life in patients who survived an out-of-hospital cardiac arrest and suffer from these symptoms",[57,58,59,60,61,28],"Cognitive Impairment","Depression, Anxiety","Cardiac Arrest","Quality of Life","Social Functioning","2026-03-25",{"date":64,"type":33},"2026-03-30",{"date":66,"type":33},"2024-08-05",{"date":68,"type":22},"2027-10-01",{"name":70,"class":71},"Azienda Usl di Bologna","OTHER_GOV",2,{"id":74,"slug":75,"hasResults":12,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":79,"eligibilityCriteria":80,"healthyVolunteers":12,"sex":50,"minAge":18,"maxAge":4,"enrollmentInfo":81,"targetDuration":4,"studyType":23,"phases":83,"briefSummary":84,"conditions":85,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":97},"100557660","a-novel-digital-application-shift-to-improve-outcomes-for-hematopoietic-stem-cell-transplant-survivors-100557660","NCT06541002","A Novel Digital Application (SHIFT) to Improve Outcomes for Hematopoietic Stem Cell Transplant Survivors","Multi-Site Randomized Controlled Trial of a Novel Digital Application (SHIFT) to Improve Outcomes for Hematopoietic Stem Cell Transplant Survivors","SHIFT","Inclusion Criteria:\n\n* Adult patients (\\> 18 years) who underwent autologous or allogeneic HCT \\> three months prior to study enrollment\n* Screen positive for sexual health concerns causing distress based on the National Comprehensive Network (NCCN) survivorship guidelines screening questions\n\nExclusion Criteria:\n\n* Patients who do not comprehend English or Spanish since SHIFT will only be available in these two languages for this efficacy trial.\n* Patients with any major uncontrolled psychiatric disorder or other comorbid cognitive conditions, which the treating HCT clinician believes would prohibit the patients' capacity to provide informed consent and participate in study procedures.\n* Patients with relapsed disease requiring treatment.",{"count":82,"type":22},300,[25],"This research study is evaluating the efficacy of a novel self-administered digital application for improving sexual health outcomes, quality of life, and psychological distress in hematopoietic stem cell transplant survivors.",[28,86,87],"Stem Cell Transplant Complications","Bone Marrow Transplant Complications","2026-03-17",{"date":90,"type":33},"2026-03-19",{"date":92,"type":33},"2025-01-27",{"date":94,"type":22},"2030-04-30",{"name":96,"class":40},"Massachusetts General Hospital",3,{"id":99,"slug":100,"hasResults":12,"nctId":101,"briefTitle":102,"officialTitle":102,"acronym":4,"eligibilityCriteria":103,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":104,"targetDuration":4,"studyType":23,"phases":106,"briefSummary":107,"conditions":108,"keywords":112,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":115,"lastUpdatePostDateStruct":116,"startDateStruct":118,"completionDateStruct":120,"leadSponsor":122,"locationsCount":97},"100520670","pre-rehabilitation-for-female-patients-undergoing-pelvic-radiotherapy-100520670","NCT06059586","Pre-Rehabilitation for Female Patients Undergoing Pelvic Radiotherapy","Inclusion Criteria:\n\n1. Female\n2. ≥ 18 years old at the time of informed consent\n3. Ability to provide written informed consent and HIPAA authorization\n4. Primary diagnosis of cervical, vaginal, vulvar, uterine, or anal cancer\n5. Candidate for curative pelvic radiation with external beam, with or without brachytherapy, per radiation oncologist's discretion\n\nNotes:\n\n* Can have prior and\u002For current modalities of treatment to address diagnosis including surgery and chemotherapy\n* Can receive radiation at any facility provided patient is able to perform Physical Therapy visits at IUH North\u002FSchwarz Cancer Center\n\nExclusion Criteria:\n\n1. Major medical illnesses or psychiatric impairments, which in the investigator's opinion will prevent administration or completion of the protocol therapy and\u002For interfere with follow-up.\n2. Not a candidate for curative radiation therapy per radiation oncologist's discretion\n3. Prior radiation therapy to the pelvis\n4. Women who are pregnant or nursing",{"count":105,"type":22},20,[25],"The purpose of this study is to examine the feasibility of adding pre-rehabilitation pelvic health physical therapy to standard of care radiation therapy treatment plan for female patients who have been diagnosed with cervical, vaginal, vulvar, uterine, or anal cancer and are a candidate for curative pelvic radiation with external beam. Participants will receive education on using a vaginal dilator for use during treatment and complete questionnaires looking at pain and sexual function.",[109,110,28,111],"Dyspareunia","Pelvic Pain","Radiation Toxicity",[113,114],"vaginal dilator","pelvic health physical therapy","2026-02-25",{"date":117,"type":33},"2026-02-27",{"date":119,"type":33},"2024-01-16",{"date":121,"type":22},"2027-06",{"name":123,"class":40},"Indiana University",{"id":125,"slug":126,"hasResults":12,"nctId":127,"briefTitle":128,"officialTitle":129,"acronym":4,"eligibilityCriteria":130,"healthyVolunteers":12,"sex":50,"minAge":131,"maxAge":132,"enrollmentInfo":133,"targetDuration":4,"studyType":23,"phases":135,"briefSummary":136,"conditions":137,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":142,"lastUpdatePostDateStruct":143,"startDateStruct":144,"completionDateStruct":146,"leadSponsor":147,"locationsCount":41},"100561259","noninvasive-spinal-cord-stimulation-for-early-sci-100561259","NCT06587841","Noninvasive Spinal Cord Stimulation for Early SCI","Noninvasive Spinal Cord Neuromodulation to Improve Lower Urinary Tract Function After Spinal Cord Injury in Ukrainian War Veterans","Inclusion Criteria:\n\n* A participant must meet all of the following criteria in order to be eligible to participate:\n\n  1. Be a resident of either British Columbia (for Vancouver Site) with an active provincial medical service plan or Ukraine (for Ukraine Site) Age between 19 and 65 years at the time of consent\n  2. Subacute (time since injury 3-6 months) or chronic (time since injury 12+ months) SCI\n  3. ASIA Impairment Scale (AIS) A or B at spinal segments C5-T10\n  4. Documented impaired LUT function\n  5. Women of childbearing potential must not be intending to become pregnant, currently pregnant, or lactating. The following conditions apply:\n\n     i. Women of childbearing potential must have a confirmed negative pregnancy test prior to the baseline visit.\n\n     ii. Women of childbearing potential must agree to use adequate contraception during the period of the trial and for at least 28 days after completion of treatment. Effective contraception includes abstinence.\n  6. Sexually active males with female partners of childbearing potential must agree to use effective contraception during the period of the trial and for at least 28 days after completion of treatment.\n  7. Must provide informed consent.\n  8. Agrees to comply with all planned visits and assessments, adhere with established bowel and LUT routines and refrain from initiation of new medications for bowel and LUT management without notifying the Principal Investigator of this study.\n\n     Exclusion Criteria:\n* A participant who meets any of the following criteria will be ineligible to participate:\n\n  1. Clinically significant depression with thoughts of suicidal ideation (PHQ-9 total score above 20) or debilitating PTSD (PCL-5 total score above) or as judged by the investigator.\n  2. History of bladder augmentation or continent or incontinent urinary stoma or prior bladder surgery.\n  3. Exhibits signs of lower motor neuron injury (i.e., concomitant conus medullaris\u002Fcauda equina injury).\n  4. History of intradetrusor or intrasphincter onabotulinumtoxinA injections within 9 months of baseline visit.\n  5. Concurrent use of any medication or treatment that in the opinion of the investigator interferes with study outcomes.\n  6. Presence of cognitive impairments, social\u002Fpsychological problems, or other comorbid conditions that, in the opinion of the Investigator, will preclude them from participation and completion of the study\n  7. Presence of severe acute medical issues that interfere with testing (e.g., stage 3\u002F4 pressure ulcers, uncontrolled diabetes).\n  8. Contraindications for TSCS, such as:\n\n     8.1. Implanted Cardiac pacemaker 8.2 Implanted metal in the trunk or spinal cord 8.3 Intrathecal delivery system (e.g., baclofen pump) 8.4 Implanted central or peripheral neuromodulator\n  9. Medical condition that may put the participant at risk as determined by the investigator.\n  10. Participation in or plans to participate in another research study that may interfere with the study endpoints.","19 Years","65 Years",{"count":134,"type":22},60,[25],"The investigators are looking to determine the safety and efficacy of non-invasive transcutaneous spinal cord stimulation (TSCS) in promoting recovery of lower urinary tract (LUT), bowel, sexual, and cardiovascular function, as well as spasticity in individuals with subacute and chronic SCI (time since injury 3-6 months) and the impact on quality of life. The study will be conducted at two sites; site 1 in Canada and site 2 in the Ukraine. Up to 60 subjects will be enrolled; 10 adults at the ICORD, University of British Columbia (UBC), Vancouver, Canada site and 50 adults at the Rivne Regional War Veterans Hospital, Rivne, Ukraine. Eligible participants will be randomized (1:1 ratio) either to Group 1 (G1) or Group 2 (G2). G1 will receive therapeutic TSCS for 8 weeks (3 times per week; 1 hour per session) in conjunction with conventional rehabilitation (3-4 hours per day; 5 days per week). G2 will receive 8 weeks of sham stimulation in conjunction with conventional rehabilitation. After 8 weeks, G2 will cross over and receive therapeutic TSCS for 8 weeks, whereas G1 will continue to receive TSCS therapy for another 8 weeks, for a total of 16 weeks. Eligible participants enrolled into the study will attend fifty eight (58) visits for assessments, therapy, and follow-up. The expected duration of study participation for each participant will be 33 weeks.",[138,139,28,140,141],"Spinal Cord Injuries","Bowel Dysfunction","Autonomic Dysfunction","Urologic Disorders","2026-02-23",{"date":117,"type":33},{"date":145,"type":33},"2024-10-01",{"date":68,"type":22},{"name":148,"class":40},"University of British Columbia",{"id":150,"slug":151,"hasResults":12,"nctId":152,"briefTitle":153,"officialTitle":154,"acronym":155,"eligibilityCriteria":156,"healthyVolunteers":157,"sex":17,"minAge":158,"maxAge":132,"enrollmentInfo":159,"targetDuration":4,"studyType":23,"phases":161,"briefSummary":162,"conditions":163,"keywords":4,"overallStatus":167,"whyStopped":4,"lastUpdateSubmitDate":168,"lastUpdatePostDateStruct":169,"startDateStruct":171,"completionDateStruct":173,"leadSponsor":175,"locationsCount":41},"100624346","transdermal-testosterone-gel-for-female-sexual-interest-and-arousal-disorder-in-peri--and-post-menopause-100624346","NCT07408440","Transdermal Testosterone Gel for Female Sexual Interest and Arousal Disorder in Peri- and Post Menopause","Transdermal Testosterone Gel for Female Sexual Interest and Arousal Disorder in Peri- and Post Menopause - A Randomized, Double-blind, Placebo-controlled Trial for Improving Sexual Interest and Desire","TESTA MIND","Inclusion Criteria\n\n* Women 40-65 years; peri- or postmenopausal - with one of the following:\n\n  * Staging by STRAW+10: stage (-2) or above\n  * amenorrhea ≥12 mo\n  * Follicle stimulating hormone in menopausal range\n* FSIAD diagnosis according to the DSM-5: (3\u002F5 of the following symptoms)\n\n  * reduced or no interest in sex\n  * few or no thoughts about sex\n  * decreased sexual arousal or pleasure during sexual activity\n  * reduced or no arousal in response to visual, written, or verbal cues\n  * infrequent or no initiation of sexual activity within a relationship\n  * reduced or no sensations in the genitals\n\nThey must also have:\n\n* symptoms lasting 6 months or more\n* significant distress about their symptoms\n* symptoms that are not more accurately explained by a nonsexual mental health disorder, domestic abuse, medication, substance abuse, or another medical condition\n\n  * In a stable relationship or sexually active opportunity (as defined by participant)\n  * If on systemic estrogen ± progestin or local vaginal estrogen: stable dose ≥8 weeks before randomization and agrees to remain stable\n  * Able to consent and comply with study procedures\n\nExclusion Criteria\n\n* Current or recent (≤8 weeks) androgen therapy, dehydroepiandrosterone (DHEA), or anabolic steroids\n* Total T above premenopausal upper physiologic range at baseline (\\>55 ng\u002FdL)\n* History of hormone-dependent malignancy, untreated endometrial hyperplasia, or active gynecologic malignancy\n* Active severe psychiatric disorder (e.g., untreated major depression), substance use disorder, or relationship violence that precludes attribution of effect\n* Uncontrolled thyroid disease, significant liver disease, increased liver enzymes, or high cardiovascular risk judged unsafe by the primary care provider\n* Pregnancy, attempting conception, or breastfeeding\n* Dermatologic conditions preventing transdermal use; known hypersensitivity to the gel components",true,"40 Years",{"count":160,"type":22},150,[25],"Hypoactive sexual desire disorder (HSDD) is described as the most common form of female sexual dysfunction, particularly affecting peri- and postmenopausal women and is associated with significant distress and reduced quality of life. The TESTA-MIND study will evaluate the efficacy and safety of a standardized compounded transdermal testosterone gel in a randomized, double-blind, placebo-controlled design to address the lack of FDA-approved options and limited high-quality evidence for treating decreased libido in women.",[164,28,165,166],"Menopause","Libido Disorder","Testosterone Deficiency","NOT_YET_RECRUITING","2026-02-12",{"date":170,"type":33},"2026-02-17",{"date":172,"type":22},"2026-04-01",{"date":174,"type":22},"2028-03-30",{"name":176,"class":40},"The University of Texas Health Science Center, Houston",{"id":178,"slug":179,"hasResults":12,"nctId":180,"briefTitle":181,"officialTitle":182,"acronym":4,"eligibilityCriteria":183,"healthyVolunteers":12,"sex":17,"minAge":158,"maxAge":4,"enrollmentInfo":184,"targetDuration":4,"studyType":23,"phases":185,"briefSummary":186,"conditions":187,"keywords":190,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":198,"lastUpdatePostDateStruct":199,"startDateStruct":200,"completionDateStruct":202,"leadSponsor":204,"locationsCount":97},"100624751","btl-699-2-and-hpm-6000uf-devices-for-the-improvement-of-depressive-symptoms-and-sexual-function-among-perimenopausal-and-postmenopausal-women-100624751","NCT07413705","BTL-699-2 and HPM-6000UF Devices for the Improvement of Depressive Symptoms and Sexual Function Among Perimenopausal and Postmenopausal Women","Safety and Efficacy of the Combined BTL-699-2 and HPM-6000UF Devices for the Improvement of Depressive Symptoms and Sexual Function Among Perimenopausal and Postmenopausal Women","Inclusion Criteria:\n\n* Menopause defined as 12 consecutive months with no menses without an alternative medical cause or perimenopause defined as occurrence of ≥ 60 days of amenorrhea without an alternative medical cause\n* Patient Health Questionnaire-9 (PHQ-9) pre-treatment score of ≥ 5\n* Age ≥ 40 years\n* Ability to determine the motor threshold of the participant. The participant's motor threshold could be established as the minimum stimulus required to induce contraction of the finger\n* Subjects willing and able to abstain from partaking in any treatments other than the pre-procedure therapy regime for the improvement of depressive symptoms and\u002For sexual function, including non-invasive brain stimulation treatments other than the study procedure during study participation\n* Willingness to comply with study instructions and to return to the clinic for the required visits\n* Women of childbearing potential\\* are required to use birth control measures during the whole duration of the study\n* If applicable, subjects will be maintained on pre-study psychotherapeutic regime, and prescribed chronic medications at a stable therapeutic dosage for at least 1 month prior to study entry \\*defined as any female who has experienced menarche and who is NOT permanently sterile or postmenopausal. Postmenopausal is defined as 12 consecutive months with no menses without an alternative medical cause.\n\nExclusion Criteria:\n\n* Metallic objects in or near the head\n* rTMS devices are contraindicated for use in patients who have conductive, ferromagnetic or other magnetic-sensitive metals implanted in their head or within 12 in (30 cm) of the treatment coil\\*\n* Implanted stimulator devices, implanted defibrillators, implanted neurostimulators\n* Cardiac pacemakers\n* Electronic implants\n* Metal implants\n* rTMS devices are contraindicated for use in patients who have active or inactive implants (including device leads), including deep brain stimulators, cochlear implants, ocular implants and vagus nerve stimulators. - Contraindicated use could result in serious injury or death.\n* Drug pumps\n* Application in the heart area\n* Application of HPM-6000UF in the head area\n* Persons with a tendency to seizure (e.g., persons suffering from hypotonia and epilepsy)\n* Anticoagulation therapy\n* Severe or life-threatening condition\n* Pulmonary insufficiency\n* Heart disorders\n* Renal insufficiency\n* Decompensated\\*\\* hemorrhagic conditions\n* Decompensated\\*\\* blood coagulation disorders\n* Decompensated\\*\\* cardiovascular diseases\n* Malignant tumor or benign tumor\n* Fever\n* Pregnancy\n\nStudy specific:\n\n* Active suicidal intent\n* History of suicide attempts in the last 3 years\n* History or concurrent use of electroconvulsive therapy or vagus nerve stimulation\n* Substance-induced depression or depression secondary to a general medical condition\n* Diagnosis of seasonal affective disorder, psychotic disorder including schizoaffective disorder or current psychotic symptoms, major depression with psychotic features, bipolar disorder\n* Substance abuse\n* Dependence 3 months prior\n* Neurological disorders, including a history of seizures, cerebrovascular disease, primary or secondary tumors in CNS, cerebral aneurysm, dementia, or movement disorders\n* History of increased intracranial pressure or head trauma\n* Nursing\n* Ongoing intake disorders such as bulimia or anorexia, or intake disorder in the past 12 months\n* Any other disease or condition at the investigator's discretion that may pose risk to the patient or compromise the study\n\n  * Examples include cochlear implants, implanted electrodes\u002Fstimulators, aneurysm clips or coils, stents, bullet fragments, jewelry and hair barrettes. - Failure to follow this restriction could result in serious injury or death. Certain exceptions apply to mouth implants such as standard amalgam dental fillings, single post dental implants, dental bridge work, and braces. If these items are present, the therapy can still be administered.\n\n    * By means of decompensation, it means a patient with a proven medical history of the decompensated health condition and long-term medication. Patients who use certain medications only for preventive purposes, without any proven previous health condition failure are not considered contraindicated.",{"count":134,"type":22},[25],"The goal of this clinical trial is to evaluate if the combined treatment with EXOMIND (BTL-699-2) and EMSELLA (HPM-6000UF) devices is able to improve depressive symptoms and sexual function in women who are perimenopausal or postmenopausal without an alternative medical cause before enrollment in the study and are aged 40 years and older. The main question it aims to answer is: Does the combined treatment with EXOMIND (BTL-699-2) and EMSELLA (HPM-6000UF) devices improve depressive symptoms and urinary incontinence? Participants will be asked to:\n\nUndergo twelve treatments Complete the Patient Health Questionnaire-9 Complete the 6-item Hamilton Depression Rating Scale Complete the Greene Climacteric Scale Complete the Therapy Comfort Questionnaire Complete the International Consultation on Incontinence Questionnaire-Urinary Incontinence Short Form Complete the Female Sexual Function Index Complete the Warwick-Edinburgh Mental Wellbeing Scale Complete the Columbia Suicide Severity Rating Scale-Screen version Complete the Subject Satisfaction Questionnaire Complete the Therapy Comfort Questionnaire",[188,189,28],"Depressive Symptoms","Urinary Incontinence",[188,191,189,28,192,193,194,195,196,197],"Depression","Sexual Function","ExoTMS","Perimenopause","Postmenopause","EMSELLA","EXOMIND","2026-02-09",{"date":170,"type":33},{"date":201,"type":33},"2025-11-20",{"date":203,"type":22},"2026-12-11",{"name":205,"class":206},"BTL Industries Ltd.","INDUSTRY",{"id":208,"slug":209,"hasResults":12,"nctId":210,"briefTitle":211,"officialTitle":211,"acronym":212,"eligibilityCriteria":213,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":214,"targetDuration":4,"studyType":23,"phases":215,"briefSummary":216,"conditions":217,"keywords":219,"overallStatus":167,"whyStopped":4,"lastUpdateSubmitDate":222,"lastUpdatePostDateStruct":223,"startDateStruct":225,"completionDateStruct":227,"leadSponsor":229,"locationsCount":41},"100421513","behavioral-intervention-for-physical-activity-and-sexual-dysfunction-in-multiple-sclerosis-100421513","NCT04768777","Behavioral Intervention for Physical Activity and Sexual Dysfunction in Multiple Sclerosis","BIPAMS-SD","Inclusion Criteria:\n\n1. Female\n2. Diagnosed of relapsing remmiting multiple sclerosis\n3. Relapse free in the past 30 days\n4. Initial confirmation of sexual dysfunction (based on a semi-structured interview on sexual dysfunction diagnostic criteria in DSM-5)\n5. Currently in a committed relationship with a partner who does not have a sexual disorder or sexual dysfunction\n6. Internet and email access\n7. Willingness to complete the questionnaires, wear the pedometer, and undergo randomization\n8. Insufficient physical activity \\[not meeting current physical activity guidelines based on a health contribution score of less than 14 units from the Godin Leisure-Time Exercise Questionnaire (GLTEQ)\\]\n9. Ability to ambulate without assistance \\[self-report and Patient-Determined Disease Steps (PDDS) score between 0 and 2 (mild ambulatory disability)\\]\n10. Age between 18 and 45 years\n11. English as primary language\n\n    \\-\n\n    Exclusion Criteria:\n\n1\\. Moderate or high risk for contraindications of possible injury or death when undertaking strenous or maximal exercise\n\n\\-",{"count":21,"type":22},[25],"The prevalence of sexual dysfunction is higher among women with multiple sclerosis (MS) than women in the general population. The presence of sexual dysfunction is associated with decreased well-being and quality of life. There is limited research supporting pharmacological and other therapeutic approaches for managing sexual dysfunction in MS. Physical activity has beneficial effects on many of the consequences of MS, and physical activity represents a promising non-pharmacological approach for managing symptoms of sexual dysfunction in MS. The proposed research examines the effect of an Internet-delivered lifestyle physical activity intervention for improving sexual dysfunction in women with MS. The research proposed, if successful, will provide evidence for the efficacy of physical activity as a translatable approach for managing sexual dysfunction among women with MS.",[218,28],"Multiple Sclerosis, Relapsing-Remitting",[220,221],"physical activity","sexual behaviour","2025-12-16",{"date":224,"type":33},"2025-12-22",{"date":226,"type":22},"2026-12-01",{"date":228,"type":22},"2026-12-30",{"name":230,"class":40},"University of Alabama at Birmingham",{"id":232,"slug":233,"hasResults":12,"nctId":234,"briefTitle":235,"officialTitle":235,"acronym":4,"eligibilityCriteria":236,"healthyVolunteers":12,"sex":237,"minAge":18,"maxAge":4,"enrollmentInfo":238,"targetDuration":240,"studyType":241,"phases":4,"briefSummary":242,"conditions":243,"keywords":252,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":258,"lastUpdatePostDateStruct":259,"startDateStruct":261,"completionDateStruct":263,"leadSponsor":265,"locationsCount":267},"100583536","canada-wide-implementation-of-a-virtual-sexual-health-and-rehabilitation-eclinic-shareclinic-for-prostate-cancer-patients-and-their-partners-100583536","NCT06877598","Canada-wide Implementation of a Virtual Sexual Health and Rehabilitation eClinic (SHAReClinic) for Prostate Cancer Patients and Their Partners","Inclusion Criteria:\n\n* Patients who are scheduled for first-line treatment for localized prostate cancer, either through radical prostatectomy (open or robotic) or radiation treatment (brachytherapy, external beam) Alone, or with adjuvant Androgen Deprivation Therapy (ADT) OR\n\n  * Patients currently undergoing active treatment for prostate cancer OR\n  * Patients who have undergone cancer treatment in the past 6 months\n  * Patients who are hormone and\u002For chemotherapy-naïve\n  * Patients who have access to a computer or smartphone with internet access\n  * Patients who are 18 years of age or older\n\nExclusion Criteria:\n\n* Patients on ADT alone as primary treatment, and\u002For patients on chemotherapy\n* Patients who lack English proficiency\n* Patients on nitrate therapy or have other contra-indications to phosphodiesterase type 5 inhibitors (PDE5i's)\n* Patients with medical conditions that would preclude safe sexual activity\n* Patients who have had previous treatment for PCa","MALE",{"count":239,"type":22},575,"12 Months","OBSERVATIONAL","The goal of this observational study is to evaluate the effectiveness of SHAReClinic, a national, virtual Sexual Health and Rehabilitation eClinic designed to support prostate cancer patients and their partners. Specifically, this study aims to assess SHAReClinic's impact on improving sexual function, satisfaction, and relational intimacy after treatment.\n\nThe primary objective is to evaluate SHAReClinic's effectiveness across participating sites and determine its role in supporting long-term sexual health and well-being.\n\nAs part of usual care, newly enrolled SHAReClinic patients will receive guided education modules and access to sexual health counselling at key recovery milestones.\n\nSHAReClinic seeks to expand access to sexual health care for prostate cancer patients across Canada by providing evidence-based, virtual sexual rehabilitation. Findings from this study will inform best practices in survivorship care and contribute to the development of a national standard for oncology sexual health interventions.",[244,245,246,28,247,248,249,250,251],"Prostate Cancer","Sexual Dysfunction, Physiological","Sexual Dysfunction, Psychological","Virtual Care","Virtual Clinic","Survivorship","Implementation of Evidence Based Programs","Implementation",[28,253,254,251,255,256,257,249],"Prostate cancer","Virtual health","Consolidated Framework for Implementation Research (CFIR)","Bio-psychosocial","Reach Effectiveness Adoption Implementation and Maintenance (RE-AIM)","2025-12-09",{"date":260,"type":33},"2025-12-11",{"date":262,"type":33},"2025-06-01",{"date":264,"type":22},"2027-12",{"name":266,"class":40},"University Health Network, Toronto",10,{"id":269,"slug":270,"hasResults":12,"nctId":271,"briefTitle":272,"officialTitle":273,"acronym":4,"eligibilityCriteria":274,"healthyVolunteers":12,"sex":50,"minAge":131,"maxAge":275,"enrollmentInfo":276,"targetDuration":4,"studyType":23,"phases":277,"briefSummary":278,"conditions":279,"keywords":285,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":287,"lastUpdatePostDateStruct":288,"startDateStruct":290,"completionDateStruct":292,"leadSponsor":294,"locationsCount":72},"100467649","non-invasive-spinal-cord-stimulation-for-recovery-of-autonomic-function-after-spinal-cord-injury-100467649","NCT05369520","Non-invasive Spinal Cord Stimulation for Recovery of Autonomic Function After Spinal Cord Injury","Non-invasive Spinal Cord Stimulation for Recovery of Autonomic Function After Spinal Cord Injury: Moving From Mechanisms to Clinical Practice","Inclusion Criteria:\n\n1. Resident of British Columbia, Canada with active provincial medical services plan.\n2. Male or female, 19-60 years of age.\n3. Chronic traumatic SCI (non-progressive, with complete motor paralysis) at or above the T6 spinal segment.\n4. \\>1-year post injury, at least 6 months from any spinal surgery.\n5. American Spinal Injury Association Impairment Scale (AIS) A, B.\n6. Stable management of spinal cord related clinical issues (i.e., spasticity management).\n7. Experience bladder, or bowel, or sexual dysfunction.\n8. No painful musculoskeletal dysfunction, unhealed fracture, pressure sore, or active infection that may interfere with testing.\n9. For women of childbearing potential, not intending to become pregnant, currently pregnant, or lactating. The following conditions apply:\n\n   1. A confirmed negative pregnancy test prior to the baseline visit. During the trial, all women of childbearing potential will undergo urine pregnancy tests at their monthly clinic visits as outlined in the schedule of events.\n   2. Use adequate contraception, or complete abstinence from sexual activities, during the period of the trial and for at least 28 days after completion of treatment.\n   3. If using combined hormonal contraception, a stable regimen during the period of the trial and for at least 28 days after completion of treatment.\n10. For sexually active males with female partners of childbearing potential, use adequate contraception, or complete abstinence from sexual activities, during the period of the trial and for at least 28 days after completion of treatment.\n11. Must provide informed consent.\n12. Willing and able to comply with all clinic visits and study-related procedures.\n13. Able to understand and complete study-related questionnaires (must be able to understand and speak English or have access to an appropriate interpreter as judged by the investigator).\n\nExclusion Criteria:\n\n1. Ventilator dependent.\n2. Signs of lower motor neuron damage (i.e. concomitant conus medullaris\u002Fcauda equina injury).\n3. Severe anemia or hypovolemia as measured by hematocrit via blood test in the last six months.\n4. History of cardiovascular, respiratory, bladder, or renal disease unrelated to SCI or presence of hydronephrosis or presence of obstructive renal stones.\n5. History of seizures\u002Fepilepsy or recurring headaches.\n6. Clinically significant, unmanaged, depression (to be screened) or ongoing drug abuse.\n7. Intrathecal baclofen pump.\n8. Oral baclofen dose greater than 60mg.\n9. Individuals that have received intradetrusor or intrasphincter onabotulinumtoxinA injections within 6 months of baseline.\n10. Any implanted metal (other than dental implants) in the skull or presence of pacemakers, stimulators, or medication pumps in the trunk.\n11. Past electrode implantation surgery.\n12. Member of the investigational team or his\u002Fher immediate family.\n13. Presence of severe acute medical issue and use of any specific medication or treatment that, in the investigator's judgement, would adversely affect the participant's participation in the study.\n14. Known allergies or sensitivities to both blue dye and beetroot powder.\n15. Known or suspected gastrointestinal obstruction.\n16. Persons with active inflammatory bowel disease or a history of bowel perforation.","60 Years",{"count":21,"type":22},[25],"This study is a pilot clinical trial to explore the efficacy of transcutaneous spinal cord stimulation (TCSCS) (proof-of-concept) in mitigating crucial autonomic dysfunctions that impact the health-related quality of life of individuals with spinal cord injury (SCI).",[280,140,28,281,282,283,284],"Spinal Cord Injury","Neurogenic Bladder Dysfunction","Neurogenic Bowel Dysfunction","Autonomic Dysreflexia","Orthostatic Hypotension",[286,280],"Neurostimulation","2025-12-01",{"date":289,"type":33},"2025-12-08",{"date":291,"type":33},"2023-10-03",{"date":293,"type":22},"2027-10",{"name":148,"class":40},{"id":296,"slug":297,"hasResults":12,"nctId":298,"briefTitle":299,"officialTitle":300,"acronym":4,"eligibilityCriteria":301,"healthyVolunteers":157,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":302,"targetDuration":4,"studyType":23,"phases":304,"briefSummary":305,"conditions":306,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":310,"lastUpdatePostDateStruct":311,"startDateStruct":313,"completionDateStruct":315,"leadSponsor":317,"locationsCount":41},"100600961","pelvic-floor-muscle-training-during-pregnancy-100600961","NCT07104292","Pelvic Floor Muscle Training During Pregnancy","PFMT During Pregnancy - Its Implementation and Effects on Pelvic Floor Disorders, Sexual Function and Obstetric Outcomes: a Hybrid Type 1 Design Randomised Controlled Trial","Inclusion Criteria:\n\n* Woman in the 1st trimester of pregnancy (up to 12+6 weeks of gestation)\n* Para 0 (no previous birth or pregnancy \\> 16 weeks of gestation)\n* Understands, writes, and reads fluently in Danish or English\n* Has a smart phone or computer\u002Ftablet to reach the training program\n\nExclusion Criteria:\n\n* Severe psychiatric illness (e.g. schizophrenia, bipolar disorder, severe depression or anxiety)\n* Active substance abuse\n* Acute social crises (e.g. homelessness, ongoing domestic violence, severe financial instability, lack of social support)\n* Women with limited capacity to provide informed consent (due to cognitive impairment or language barriers)\n* Previous pregnancy of \\> 16 weeks of gestation",{"count":303,"type":22},734,[25],"The project seeks to investigate effectiveness of PFMT during pregnancy.",[307,189,308,309,28],"Pelvic Floor","Anal Incontinence","Pelvic Organ Prolapse","2025-11-21",{"date":312,"type":33},"2025-11-28",{"date":314,"type":33},"2025-10-27",{"date":316,"type":22},"2028-08-01",{"name":318,"class":40},"University of Southern Denmark",{"id":320,"slug":321,"hasResults":12,"nctId":322,"briefTitle":323,"officialTitle":324,"acronym":4,"eligibilityCriteria":325,"healthyVolunteers":157,"sex":50,"minAge":18,"maxAge":326,"enrollmentInfo":327,"targetDuration":4,"studyType":23,"phases":328,"briefSummary":329,"conditions":330,"keywords":331,"overallStatus":167,"whyStopped":4,"lastUpdateSubmitDate":337,"lastUpdatePostDateStruct":338,"startDateStruct":340,"completionDateStruct":342,"leadSponsor":344,"locationsCount":4},"100604694","developing-a-psychosexual-education-app-with-artificial-intelligence-100604694","NCT07152847","Developing a Psychosexual Education App With Artificial Intelligence","Developing a Psychosexual Education App With Artificial Intelligence for National Health Service Patients on a Psychosexual Services Waiting List: A Pilot Pre Test Post Test Study","Inclusion Criteria:\n\n* Must be aged 18 years and above\n* Must have a laptop, computer, or mobile phone. The App can only be accessed on smartphones and laptops.\n* Must have been referred to the National Health Service with a psychosexual presentation\n* Must be currently awaiting psychosexual therapy\n* Must have been on a National Health Service psychosexual waiting list for less than one month\n* Must be fluent in reading and writing English, as this is a clinical trial, the investigators wanted to ensure that participants fully understand what was expected.\n* The Patient Health Questionnaire 2 screening for depression must have a score range between 0 to 2 negative\n* The Generalised Anxiety Disorder questionnaire 2 screening for anxiety must have a score range between 0 to 2 negative\n\nExclusion Criteria:\n\n* Aged below 18 years\n* Do not possess a mobile phone, computer or laptop\n* Are not part of a National Health Service referral system\n* Do not have a psychosexual presentation\n* Are currently or starting psychosexual therapy\n* Have difficulties understanding or speaking English\n* The Patient Health Questionnaire 2 screening outcomes 3 and above\n* The Generalised Anxiety Disorder questionnaire 2 screening outcomes 3 and above","100 Years",{"count":160,"type":22},[25],"The goal of this clinical trial is to establish the effectiveness of a resource based educational psychosexual app for patients attending a waiting list for psychosexual therapy. The app will provide information on sexual dysfunction, kegel exercises, cognitive and mindfulness exercises, along with suitable resources providing information on sexual functioning for men and women. The app will integrate artificial intelligence to improve user experience and efficiency.\n\nThe current waiting lists for the National Health Service Psychosexual services are approximately 6 months. Based on this, a pre test post test study measuring participants' sexual functioning, well being, cognitive mindfulness and quality of life will be taken at points 0, 8 and 16 weeks.\n\nOutcomes will assess whether the app was sufficient for these domains. This might further reduce the strain on the National Health Service's resources.\n\nIt is hypothesised that app use from weeks 0, 8, and 16 follow up will improve sexual functioning, well being, quality of life, and cognitive mindfulness.",[28],[332,333,334,335,336],"Psychosexual app","Artificial intelligence","Cognitive mindfulness","Well being","Quality of life","2025-09-03",{"date":339,"type":33},"2025-09-10",{"date":341,"type":22},"2026-09",{"date":343,"type":22},"2027-03",{"name":345,"class":40},"London Metropolitan University",{"id":347,"slug":348,"hasResults":12,"nctId":349,"briefTitle":350,"officialTitle":351,"acronym":4,"eligibilityCriteria":352,"healthyVolunteers":12,"sex":237,"minAge":18,"maxAge":4,"enrollmentInfo":353,"targetDuration":4,"studyType":23,"phases":355,"briefSummary":356,"conditions":357,"keywords":4,"overallStatus":167,"whyStopped":4,"lastUpdateSubmitDate":337,"lastUpdatePostDateStruct":359,"startDateStruct":361,"completionDateStruct":363,"leadSponsor":365,"locationsCount":41},"100565105","sexual-and-urinary-function-improvement-for-cancer-survivors-100565105","NCT06637852","Sexual and Urinary Function Improvement for Cancer Survivors","Sexual and Urinary Function Improvement for Cancer Survivors- Promoting Access to Collaborative Treatment (SUFICS-PACT)","Inclusion Criteria:\n\n* At least 18 years old\n* Have a diagnosis of prostate cancer\n* Have sought care\u002Ftreatment for prostate cancer\n\nExclusion Criteria:\n\n* Patients under 18 years old\n* Patients who have not sought care\u002Ftreatment for prostate cancer\n* Patients who are categorized as \"vulnerable subjects,\" such as minors or incarcerated individuals.",{"count":354,"type":22},200,[25],"The purpose of this study is to test the efficacy of SUFICS-PACT to identify and treat sexual and urinary dysfunction in prostate cancer survivors at NYC H+ H\u002FBellevue, the oldest public hospital in the US. This study will evaluate the implementation of an adapted sexual and urinary function collaborative care model at NYC Health+Hospitals\u002FBellevue. The study will test the efficacy of this collaborative care model through a randomized controlled trial in the adult primary care clinic; the intervention arm will receive collaborative treatment consisting of a care manager who has specialty training in mental health and psychosexual counseling, a primary care nurse practitioner who leads symptom management, primary care physicians who supervise the team, and a team specialty consult liaison.",[358,28],"Urinary Dysfunction",{"date":360,"type":33},"2025-09-05",{"date":362,"type":22},"2026-10-01",{"date":364,"type":22},"2030-03-31",{"name":366,"class":40},"NYU Langone Health",{"id":368,"slug":369,"hasResults":12,"nctId":370,"briefTitle":371,"officialTitle":372,"acronym":4,"eligibilityCriteria":373,"healthyVolunteers":12,"sex":17,"minAge":374,"maxAge":19,"enrollmentInfo":375,"targetDuration":4,"studyType":23,"phases":377,"briefSummary":378,"conditions":379,"keywords":4,"overallStatus":167,"whyStopped":4,"lastUpdateSubmitDate":381,"lastUpdatePostDateStruct":382,"startDateStruct":384,"completionDateStruct":386,"leadSponsor":388,"locationsCount":41},"100604107","effect-of-knack-pelvic-floor-contraction-on-sexual-dysfunction-100604107","NCT07145216","Effect of Knack Pelvic Floor Contraction on Sexual Dysfunction","Effect of Knack Pelvic Floor Contraction on Sexual Dysfunction in Females With Stress Urinary Incontinence","Inclusion Criteria:\n\n1. Females with mild and moderate degrees of SUI according to Incontinence Severity Index score (mild: 1-2; and moderate: 3-4 scoring).\n2. Their ages will range from 25 to 45 years old.\n3. Their body mass index (BMI) will be less than 30 kg\u002Fm2.\n4. They are multiparous women.\n5. Females complain of sexual disorders related to SUI, identified by an FSFI score of less than 28.1\n6. They have a sedentary lifestyle.\n\nExclusion Criteria:\n\n1. Severe degree of SUI.\n2. Other types of urinary incontinence, such as urge urinary incontinence and mixed urinary incontinence.\n3. Other neurological diseases such as myasthenia gravis and Parkinsonism.\n4. History of pelvic fractures.\n5. Menopausal women.\n6. Females with pelvic organ prolapse (POP).","25 Years",{"count":376,"type":22},40,[25],"This study aims to investigate the effect of knack pelvic floor contraction on sexual dysfunction in females with stress urinary incontinence.",[380,28],"Stress Urinary Incontinence (SUI)","2025-08-21",{"date":383,"type":33},"2025-08-28",{"date":385,"type":22},"2025-09-01",{"date":387,"type":22},"2026-01-30",{"name":389,"class":40},"Cairo University",{"id":391,"slug":392,"hasResults":12,"nctId":393,"briefTitle":394,"officialTitle":395,"acronym":396,"eligibilityCriteria":397,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":398,"enrollmentInfo":399,"targetDuration":400,"studyType":241,"phases":4,"briefSummary":401,"conditions":402,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":405,"lastUpdatePostDateStruct":406,"startDateStruct":408,"completionDateStruct":410,"leadSponsor":411,"locationsCount":41},"100551336","sexual-dysfunction-check-up-in-premenopausal-breast-cancer-survivors-taking-endocrine-therapy-a-cross-sectional-study-100551336","NCT06458764","Sexual Dysfunction Check-up in Premenopausal Breast Cancer Survivors Taking Endocrine Therapy: A Cross-Sectional Study","SEXCHECK - Sexual Dysfunction Check-up in Premenopausal Breast Cancer Survivors Taking Endocrine Therapy: A Cross-Sectional Study","SEXCHECK","Inclusion Criteria:\n\n* women aged ≥18 and ≤ 55\n* who underwent surgery for early stage breast cancer\n* taking endocrine therapy for at least 3 months\n* providing an informed consent and completing the study questionnaires.\n\nExclusion Criteria:\n\n* withdrawal of the informed consent, at any time","55 Years",{"count":160,"type":22},"1 Month","Primary objectives:\n\n* To estimate Sexual Dysfunction (SD) incidence in premenopausal breast cancer patients treated by surgery and taking endocrine therapy.\n* To detect the presence of SD-related distress in the population, as a determining factor in the maintenance of a good quality of life.\n\nSecondary objectives:\n\n* To describe SD characteristics determining the most frequently reported symptoms and correlations with type of surgery or therapeutic regimens.\n* Collect baseline data for subsequent randomized trials involving practical interventions with the aim to reduce SD prevalence in this population.",[403,28,404],"Breast Cancer Female","Premenopausal Breast Cancer","2025-06-18",{"date":407,"type":33},"2025-06-24",{"date":409,"type":33},"2023-05-01",{"date":287,"type":22},{"name":412,"class":40},"Candiolo Cancer Institute - IRCCS",{"id":414,"slug":415,"hasResults":12,"nctId":416,"briefTitle":417,"officialTitle":417,"acronym":4,"eligibilityCriteria":418,"healthyVolunteers":12,"sex":237,"minAge":18,"maxAge":4,"enrollmentInfo":419,"targetDuration":4,"studyType":23,"phases":421,"briefSummary":422,"conditions":423,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":427,"lastUpdatePostDateStruct":428,"startDateStruct":430,"completionDateStruct":432,"leadSponsor":434,"locationsCount":41},"100475285","prostate-stimulation-for-sexual-dysfunction-100475285","NCT05468931","Prostate Stimulation for Sexual Dysfunction","Inclusion Criteria:\n\n* Males \\>18 years of age suffering from sexual dysfunction\n\nExclusion Criteria:\n\n* Individuals who have had a prostatectomy - removal of prostate\n* Inability to operate the device for any reason\n* Females\n* Males \\\u003C18 years of age",{"count":420,"type":22},15,[25],"The purpose of this study is to use a device to stimulate the prostate with a goal of helping improve symptoms in men with sexual dysfunction.",[28,424,425,426],"Erectile Dysfunction","Delayed Ejaculation","Anorgasmia","2025-05-28",{"date":429,"type":33},"2025-06-03",{"date":431,"type":33},"2024-04-18",{"date":433,"type":22},"2026-06-01",{"name":435,"class":40},"Stanford University",{"id":437,"slug":438,"hasResults":12,"nctId":439,"briefTitle":440,"officialTitle":441,"acronym":4,"eligibilityCriteria":442,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":443,"enrollmentInfo":444,"targetDuration":4,"studyType":23,"phases":446,"briefSummary":447,"conditions":448,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":456,"lastUpdatePostDateStruct":457,"startDateStruct":459,"completionDateStruct":461,"leadSponsor":463,"locationsCount":41},"100497748","assessment-of-womens-sexual-quality-of-life-after-benign-adnexal-surgery-using-vnotes-approach-100497748","NCT05761275","Assessment of Women's Sexual Quality of Life After Benign Adnexal Surgery Using vNOTES Approach","Assessment of Women's Sexual Quality of Life After Benign Adnexal Surgery Using vNOTES Approach in Comparison to Conventional Laparoscopy: a Randomized Controlled Trial","Inclusion Criteria:\n\n* Women aged from 18 to 70 years\n* Discernment capacity with oral and written consent signed\n* Heterosexual intercourse (with vaginal penetration) within four weeks prior to inclusion in the study\n\nExclusion Criteria:\n\n* History of rectal surgery.\n* Suspected rectovaginal\u002Fretrocervical endometriosis.\n* History of brachytherapy or pelvic radiation.\n* Suspected malignancy.\n* History of severe pelvic inflammatory disease.\n* Active lower genital tract infection.\n* Pregnancy.\n* Women who do not speak fluent French or English.\n* Patients under tutelage (with or without capacity of judgement).","70 Years",{"count":445,"type":22},62,[25],"Transvaginal Natural Orifice Transluminal Endoscopic Surgery (vNOTES) is a recent innovation in minimally invasive surgery which has already proven its non-inferiority to conventional abdominal laparoscopy (CAL) for hysterectomy in terms of efficiency and safety. However, the investigators note a lack of medical literature and no specific randomized controlled trial (RCT) assessing women's sexual function after vNOTES for benign adnexal surgery.\n\nThe aim of this RCT is to confirm the non-inferiority of the vNOTES approach for benign adnexal pathology compared to CAL on women's sexual function. Secondary outcomes will evaluate vNOTES's efficiency, morbidity and postoperative complications compared to CAL for benign adnexal surgery. The relationship between adnexal mass morcellation\u002Faspiration and the quality of the histological analysis on surgical specimens will also be evaluated as secondary outcome.",[449,450,451,452,453,28,60,454,109,110,455],"Gynecologic Disease","Adnexal Mass","Adnexal Cyst","Sexuality","Adnexal Diseases","Pathology","Complication","2025-03-24",{"date":458,"type":33},"2025-03-27",{"date":460,"type":33},"2024-01-01",{"date":462,"type":22},"2027-04-03",{"name":464,"class":40},"Jean Dubuisson",{"id":466,"slug":467,"hasResults":12,"nctId":468,"briefTitle":469,"officialTitle":470,"acronym":4,"eligibilityCriteria":471,"healthyVolunteers":12,"sex":50,"minAge":18,"maxAge":51,"enrollmentInfo":472,"targetDuration":4,"studyType":23,"phases":473,"briefSummary":474,"conditions":475,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":479,"lastUpdatePostDateStruct":480,"startDateStruct":482,"completionDateStruct":484,"leadSponsor":486,"locationsCount":41},"100468520","sacral-neuromodulation-for-neurogenic-lower-urinary-tract-bowel-and-sexual-dysfunction-100468520","NCT05380856","Sacral Neuromodulation for Neurogenic Lower Urinary Tract, Bowel and Sexual Dysfunction","Sacral Neuromodulation for Patients With Multiple Sclerosis With Neurogenic Lower Urinary Tract, Bowel and Sexual Dysfunction. A Multicenter Double-blind, Placebo-controlled Randomized Clinical Trial.","Inclusion Criteria:\n\n* Refractory neurogenic lower urinary tract dysfunction (nLUTD) defined by visual analogue scale on treatment satisfaction ranging from 0 to 100 (100 means maximal satisfaction with the current treatment). All patients indicating satisfaction less than 50 are considered non-responders\u002Fhaving refractory overactive bladder (OAB) to current treatment\n* No effect of medical treatment defined by antimuscarinics, beta3-agonist and alpha-blocker.\n* Patients having refractory nLUTD who intend to try SNM for relief of their symptoms\n* Expanded Disability Status Scale (EDSS) \\\u003C 5 and no progression of neurological disease within 6 months\n* Written informed consent\n* Able to understand the information given about the project\n\nExclusion Criteria:\n\n* EDSS \\> 5, neurological disease with severe progression within the last 6 months and\u002For unable to manage the electronic devices\n* Age \\\u003C 18 years\n* Any other urological pathology but nLUTD\n* Bladder Pain Syndrome\u002FInterstitial cystitis\n* Any other intestinal or gynecological pathology but neurological conditional symptoms\n* Current pelvic malignancy or clinically significant pelvic mass\n* Previous pelvis radiotherapy\n* Bladder injections with botulinum neurotoxin type A within 6 months before inclusion in trial\n* Unable to manage the electronic devices\n* Inability to give an informed consent",{"count":134,"type":22},[25],"A multi-center double-blinded placebo-controlled randomized clinical trial.\n\nThe patients will be randomized into two groups.\n\nTo investigate the efficacy of SNM to improve the key bladder diary variables compared to placebo (i.e. sham) for patients with MS having refractory neurogenic lower urinary tract dysfunction (NLUTD).\n\nAfter first step SNM-procedure and a 3-4 weeks test period patients with more than 50% improvement in the key bladder diary variables will have the IPG implanted. After a month of optimization patients will into two groups: IPG ON or IPG OFF.\n\nPeriod of randomization: four months. Number anticipated to be included: 60 patients",[476,477,478,139,28,60],"Neurogenic Dysfunction of the Urinary Bladder","Multiple Sclerosis","Sacral Neuromodulation","2025-03-17",{"date":481,"type":33},"2025-03-20",{"date":483,"type":33},"2023-09-26",{"date":485,"type":22},"2027-03-01",{"name":487,"class":40},"Odense University Hospital",{"id":489,"slug":490,"hasResults":12,"nctId":491,"briefTitle":492,"officialTitle":493,"acronym":494,"eligibilityCriteria":495,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":496,"targetDuration":4,"studyType":23,"phases":497,"briefSummary":498,"conditions":499,"keywords":505,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":509,"lastUpdatePostDateStruct":510,"startDateStruct":512,"completionDateStruct":514,"leadSponsor":516,"locationsCount":72},"100579306","pelvic-health-rehabilitation-after-breast-and-gynecologic-cancer-100579306","NCT06822582","Pelvic Health Rehabilitation After Breast and Gynecologic Cancer","A Pelvic Health eModule to Address Urogenital Impairments After Breast and Gynecologic Cancer: a Pilot Prospective Interventional Study","GYVE","Inclusion Criteria:\n\n* be \\>18 years of age;\n* have received a diagnosis of breast or gynecological (endometrial, cervical, ovarian, vulvar or vaginal) cancer (Stage I-IV) ;\n* be on active cancer treatment or have completed any cancer treatment (surgery and\u002For radiation therapy and\u002For chemotherapy) within the last 3 years;\n* be able to provide informed written consent in English or French;\n* have a urogenital dysfunction, as screened by a score of ≥ 2 on the Pelvic Floor Bother Questionnaire.\n\nExclusion Criteria:\n\n* do not have regular access to internet, to a smart device or a computer, at home.",{"count":105,"type":22},[25],"The GYVE study aims at testing an online program (eModule) to help people who have had breast or gynecologic cancer and are experiencing pelvic health issues like urinary incontinence and pain during sex. These cancers and their treatments can cause significant pelvic health problems, affecting daily life and quality of life. Physiotherapy can help, but access is often limited due to costs and other barriers. The study will involve 20 participants from Quebec and Edmonton, who will take part in a 12-week program with weekly online group sessions led by a physiotherapist. Topics include pelvic floor muscle training, use of vaginal moisturizers, hydration, diet, and pain management. Led by experts in cancer rehabilitation and pelvic health, the study aims to provide valuable information on the feasibility and effectiveness of the eModule, potentially leading to broader implementation to help more people with lived experience of cancer.",[500,403,501,502,28,503,504],"Gynecologic Cancers","Incontinence","Incontinence Bowel","Vaginal Atrophy, Sexual Dysfunction, Vaginal Dryness, Dyspareunia","Constipation",[506,507,508],"pelvic health","telerehabilitation","supportive cancer care","2025-02-11",{"date":511,"type":33},"2025-02-12",{"date":513,"type":33},"2025-01-07",{"date":515,"type":22},"2026-06",{"name":517,"class":40},"Laval University",{"id":519,"slug":520,"hasResults":12,"nctId":521,"briefTitle":522,"officialTitle":523,"acronym":524,"eligibilityCriteria":525,"healthyVolunteers":12,"sex":50,"minAge":18,"maxAge":4,"enrollmentInfo":526,"targetDuration":4,"studyType":23,"phases":528,"briefSummary":529,"conditions":530,"keywords":537,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":542,"lastUpdatePostDateStruct":543,"startDateStruct":544,"completionDateStruct":546,"leadSponsor":548,"locationsCount":41},"100512377","sex-psychopharmacology-and-diabetes-100512377","NCT05951660","Sex, Psychopharmacology, and Diabetes","The Effect of Targeted Education on Number, Severity, and Perception of Sexual Side Effects of Patients Suffering From Schizophrenia and Diabetes or Prediabetes.","SECRET","Inclusion Criteria:\n\n* Age ≥ 18 years\n* A diagnosis in the schizophrenic spectrum (ICD10 F2x)\n* One of the following:\n\n  1. A diagnosis of diabetes (ICD10 E10x, E11x, E12x, E13x, 14x)\n  2. A current or previous prediabetes defined as an HbA1c between 39-47 mmol\u002Fmol (both included) measured in at least two blood samples collected with ≥3 months intervals as part of the patient's routine clinical monitoring\n  3. Obesity defined as a Body-Mass Index (BMI) ≥30 kg\u002Fm2\n* Ongoing treatment with at least one antipsychotic agent\n* A SD that can be rated using Changes in Sexual Function Questionnaire-14 (CSFQ-14)\n\nExclusion Criteria:\n\n* Incapacitated or subject to mental health probation\n* Unable to speak danish",{"count":527,"type":22},256,[25],"The term sexual (SD) dysfunction covers conditions that prevent people from having a satisfactory sex life. SD is a frequent and sometimes debilitating complication of mental illness and a known adverse reaction to psycho-pharmacological treatment. SD is also associated with diabetes, a common somatic comorbidity in psychiatric patients. SD is associated with both reduced quality-of-life and reduced treatment adherence, yet SD is far too rarely addressed between the patient and the healthcare professional in clinical consultations.\n\nThe purpose of the study is to investigate whether targeted education of patients with schizophrenia and diabetes\u002Fprediabetes and\u002For their healthcare professionals in causes and management of SD:\n\n* Increases the number of systematic examinations of sexual side effects,\n* Causes changes in the psycho-pharmacological treatment, and\n* Reduces the severity or perception of sexual side effects.\n\nThe study is a multicenter Randomized Controlled Trial (RCT) with four arms, in which the educational intervention is provided to patients, healthcare professionals, or both groups. The effect of the educational intervention is compared to a non-educated control group. The study is expected to include 192 patients recruited from 16 assertive community treatment centers evenly distributed in four Danish regions.\n\nThe study is part of an interdisciplinary project named SECRET. The educational intervention was developed in an ethnographic pre-study incorporating stakeholder engagement. Parallel to the present RCT, an ethnographic field study will be carried out to broaden the perspective on the effects of the intervention.",[531,532,533,534,28,535,536],"Schizophrenia","Schizophrenia Spectrum and Other Psychotic Disorders","Diabetes Mellitus","PreDiabetes","Drug-Related Side Effects and Adverse Reactions","Education",[538,539,540,541],"Randomized Controlled Trial","Treatment Adherence and Compliance","Antipsychotic Agents","Patient Education as Topic","2025-02-07",{"date":509,"type":33},{"date":545,"type":33},"2023-08-24",{"date":547,"type":22},"2025-07-31",{"name":549,"class":40},"Zealand University Hospital",{"id":551,"slug":552,"hasResults":12,"nctId":553,"briefTitle":554,"officialTitle":555,"acronym":4,"eligibilityCriteria":556,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":557,"targetDuration":4,"studyType":23,"phases":558,"briefSummary":559,"conditions":560,"keywords":561,"overallStatus":167,"whyStopped":4,"lastUpdateSubmitDate":563,"lastUpdatePostDateStruct":564,"startDateStruct":566,"completionDateStruct":568,"leadSponsor":570,"locationsCount":41},"100569430","feasibility-of-addressing-sexual-dysfunction-in-women-with-breast-and-gynecologic-cancers-with-a-novel-mobile-application-100569430","NCT06694142","Feasibility of Addressing Sexual Dysfunction in Women with Breast and Gynecologic Cancers with a Novel Mobile Application","Not Always ROSY-Feasibility of Addressing Sexual Dysfunction in Women with Breast and Gynecologic Cancers with a Novel Mobile Application","Inclusion Criteria:\n\n* Patient with a current or historic diagnosis of breast cancer or gynecologic cancer (uterine ovarian, fallopian tube, peritoneal, cervical, vulva, or vaginal cancers)\n* Agree to participate in the study with completion of survey and use of ROSY mobile application\n\nExclusion Criteria:\n\n* Currently pregnant\n* Non-English speaking (ROSY is currently is only available is in English).",{"count":105,"type":22},[25],"The purpose of this study is to identify breast and gynecologic cancer patients with sexual dysfunction, to measure sexual dysfunction with the Female Sexual Function Index (FSFI) and to provide Patients with the opportunity during this six-month period to follow up with a healthcare provider to discuss the sexual dysfunction needs and to see if a medical intervention can be of aid.",[28],[562],"breast and gynecologic cancer patients","2024-11-16",{"date":565,"type":33},"2024-11-19",{"date":567,"type":22},"2024-11-18",{"date":569,"type":22},"2026-05-18",{"name":176,"class":40},{"id":572,"slug":573,"hasResults":12,"nctId":574,"briefTitle":575,"officialTitle":575,"acronym":4,"eligibilityCriteria":576,"healthyVolunteers":12,"sex":50,"minAge":18,"maxAge":4,"enrollmentInfo":577,"targetDuration":4,"studyType":241,"phases":4,"briefSummary":579,"conditions":580,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":583,"lastUpdatePostDateStruct":584,"startDateStruct":586,"completionDateStruct":588,"leadSponsor":590,"locationsCount":41},"100519676","blood-specimen-collection-for-laboratory-assay-research-100519676","NCT06046651","Blood Specimen Collection For Laboratory Assay Research","Inclusion Criteria:\n\n* Any gender, in good general health\n* Must be 18 years old or older, inclusive at enrollment\n* Must be willing to provide capillary blood samples via a fingerstick and venous blood samples, including self-collection and collection by a licensed healthcare professional\n* Must be able to read, understand, and willingly sign an Informed Consent Form (ICF) and complete a brief health questionnaire\n* Must be able to read, speak and understand English\n* Must be available to attend one study visit at Investigator's laboratory or a third-party laboratory designated by the Investigator or collect samples at home, at the discretion of the Investigator.\n\nExclusion Criteria:\n\n* Individuals who are unable to provide a blood sample due to any illness\n* Individuals participating in another research study, that the Investigator feels may compromise study outcomes\n* Individuals having an acute or chronic disease or medical condition, including pregnancy, which could excessively increase study risk in the opinion of the Investigator or compromise study outcomes\n* Individuals who are unlikely to be available for the duration of the study",{"count":578,"type":22},10000,"To collect lab data from capillary and venous blood specimens for use in analytical research studies to support the development and validation of laboratory procedures.",[581,28,582,454],"General; Metabolic Disorder","Hair Loss","2024-11-13",{"date":585,"type":33},"2024-11-14",{"date":587,"type":33},"2023-08-16",{"date":589,"type":22},"2033-08-15",{"name":591,"class":206},"Roman Health Ventures Inc.",{"id":593,"slug":594,"hasResults":12,"nctId":595,"briefTitle":596,"officialTitle":597,"acronym":4,"eligibilityCriteria":598,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":599,"targetDuration":4,"studyType":241,"phases":4,"briefSummary":600,"conditions":601,"keywords":605,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":617,"lastUpdatePostDateStruct":618,"startDateStruct":620,"completionDateStruct":622,"leadSponsor":623,"locationsCount":41},"100565253","sexual-functioning-after-erection-prosthesis-placement-in-post-phalloplasty-transgender-persons-100565253","NCT06639776","Sexual Functioning After Erection Prosthesis Placement in Post Phalloplasty Transgender Persons","Sexual Functioning After Erection Prosthesis Placement in Post Phalloplasty Transgender Persons: a Retrospective Cohort","Inclusion Criteria:\n\n* Patient and partner age ≥ 18 years.\n* Transgender or gender non-conforming individuals diagnosed according to the DSM-5 diagnostic criteria for gender dysphoria.\n* Patients have undergone phalloplasty as a form of genital gender affirming surgery (any type of flap combination or technique is allowed).\n* Erection prosthesis placement ≥ 6 months after phalloplasty, performed at the Ghent University Hospital. Any type of prosthesis is allowed.\n* Patient has a functional erectile prosthesis at the time of the study. Number of erectile prosthesis is not relevant for inclusion.\n* Patient is Dutch, English or French speaking.\n* Voluntary signed and written consent by patient and their optional partner.\n\nExclusion Criteria:\n\n* Patient age \\< 18 years.\n* Cisgender patients treated with phalloplasty and\u002For erection prosthesis for various reasons.\n* The erection prosthesis has been explanted or the current prosthesis is nonfunctional at time of data assessment.\n* Erection prosthesis placement \\< 6 months before study start will be excluded.",{"count":160,"type":22},"This study aims to explore sexual satisfaction among transgender men and their partners following the placement of erectile prostheses after phalloplasty. While phalloplasty can create a neophallus, the lack of natural erectile tissue often necessitates the use of erectile aids, including internal prostheses. However, these prostheses, originally designed for cisgender men, face challenges when used in transgender patients, such as higher risks of complications, infections, and mechanical failures. Despite these issues, some studies report high patient satisfaction, though partner satisfaction rates are significantly lower. The study will use validated and non-validated questionnaires to assess satisfaction with various types of erectile prostheses, addressing the gap in understanding how these devices impact the sexual and relational functioning of both transgender men and their partners. These questionnaires will be provided to all included patients that are minimum 6 months after placement of an internal erection prosthesis and have a functional erection prosthesis in place",[602,424,603,604,28],"Transgenderism","Prosthesis Durability","Gender Dysphoria",[606,607,608,609,610,611,612,613,614,615,616],"Gender dysphoria","Transgender","Phalloplasty","Erectile dysfunction","Sexual function","Erection prosthesis","Penile epithesis","Medical device","Penile splint","Genital reconstruction","Patient Reported Outcome Measures (PROMs)","2024-10-11",{"date":619,"type":33},"2024-10-15",{"date":621,"type":33},"2024-07-15",{"date":547,"type":22},{"name":624,"class":40},"University Hospital, Ghent",{"id":626,"slug":627,"hasResults":12,"nctId":628,"briefTitle":629,"officialTitle":630,"acronym":631,"eligibilityCriteria":632,"healthyVolunteers":157,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":633,"targetDuration":4,"studyType":241,"phases":4,"briefSummary":635,"conditions":636,"keywords":637,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":617,"lastUpdatePostDateStruct":641,"startDateStruct":642,"completionDateStruct":644,"leadSponsor":646,"locationsCount":41},"100565252","erectile-aid-use-in-post-phalloplasty-and-post-metoidioplasty-transgender-patients-100565252","NCT06639763","Erectile Aid Use in Post-phalloplasty and Post-metoidioplasty Transgender Patients","Erectile Aid Use in Post-phalloplasty and Post-metoidioplasty Transgender Patients: an Epidemiological Survey","AID","Inclusion Criteria:\n\n* Patient and partner age ≥ 18 years.\n* Transgender or gender non-conforming individuals (and their partners).\n* Patients have undergone phalloplasty or metoidioplasty as a form of genital gender affirming surgery.\n* ≥6 months after phalloplasty or metoidioplasty (any type of flap or technique is allowed).\n* Sexually active or has been sexually active since phalloplasty or metoidioplasty with a partner or main sexual partner.\n* Voluntarily agreed that the data may be used for an anonymized scientific study.\n\nExclusion Criteria:\n\n* Patient age \\< 18 years.\n* Cisgender patients treated with phalloplasty or metoidioplasty for various reasons.\n* \\<6 months after phalloplasty or metoidioplasty.\n* Not sexually active since phalloplasty\u002Fmetoidioplasty.\n* Patient and\u002For partner have no interest in penetrative sexual intercourse.",{"count":634,"type":22},1000,"This study seeks to explore the various methods used by transgender men for sexual intercourse following phalloplasty or metoidioplasty, focusing on their satisfaction with different erectile aids, as well as the satisfaction of their partners. Phalloplasty and metoidioplasty are gender-affirming surgeries that often require additional aids to achieve the desired sexual function, particularly for penetration. While internal erectile prostheses are common after phalloplasty, they come with high complication rates, leading some patients to opt for non-surgical aids. However, the effectiveness and comfort of these aids are not well-documented. This study aims to fill this gap by examining the types of aids transgender men use, how well these aids meet their sexual needs, and how satisfied both they and their partners are with the outcomes, providing much-needed insight for healthcare providers and patients alike.",[602,424,604,28],[606,607,608,638,609,610,615,639,640,616,611,612],"Metoidioplasty","Reconstructive urology","Erectile aid",{"date":619,"type":33},{"date":643,"type":33},"2024-07-06",{"date":645,"type":22},"2025-06-30",{"name":624,"class":40},{"id":648,"slug":649,"hasResults":12,"nctId":650,"briefTitle":651,"officialTitle":651,"acronym":652,"eligibilityCriteria":653,"healthyVolunteers":157,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":654,"targetDuration":4,"studyType":23,"phases":655,"briefSummary":656,"conditions":657,"keywords":658,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":659,"lastUpdatePostDateStruct":660,"startDateStruct":661,"completionDateStruct":663,"leadSponsor":665,"locationsCount":72},"100507143","epithesis-versus-prosthesis-in-post-phalloplasty-transgender-patients-100507143","NCT05883553","Epithesis Versus Prosthesis in Post-phalloplasty Transgender Patients.","EROS","Inclusion Criteria:\n\n* Transgender or gender non-conforming individuals diagnosed according to the DSM-5 diagnostic criteria for gender dysphoria.\n* Patients have undergone phalloplasty as a form of genital gender affirming surgery.\n* ≥ 1 year after phalloplasty (any type of flap combination is allowed), performed at the Ghent University Hospital or Amsterdam UMC.\n* ≥ 3 months after coronaplasty and having reasonably pronounced coronal ridge, as defined by the surgeons' expert opinion (This criterion is only obligatory in the eptithesis group, not in the prosthesis group).\n* Anatomic penile length and girth as defined by the surgeons' expert opinion.\n* Absence of urethral stricture or other structural problem resulting in voiding dysfunction.\n* Normal uroflowmetry and post-void residue\n* Regain of at least minimal protective sensation up to the tip of the phallus as defined by Semmes-Weinstein monofilament testing.\n* Established (primary) sexual relationship with partner who is willing to take part in the study.\n* Both patient and partner have interest in penetrative sexual intercourse.\n* Patient is unable to penetrate the partner (anal or vaginal) adequately sexually without the aid of supportive measures (condom, taping, penile sleeve, penile epithesis or any other measure defined as supportive by the investigators).\n* Fit and eligible for erection prosthesis surgery, based on the surgeons' expert opinion.\n* No history of erection prosthesis surgery.\n* No interest in or fear of prosthesis surgery making this option obsolete (This criterion is only obligatory in the eptithesis group, not in the prosthesis group)\n* Treatment naïve in the use of the Elatortm or Erektortm epithesis.\n* Voluntarily signed written informed consent according to the rules of Good Clinical Practice (Declaration of Helsinki) and national regulations.\n\nExclusion Criteria:\n\n* Cisgender patients treated with phalloplasty various reasons.\n* Post-metoidioplasty patients (metoidioplasty as step-up to performed phalloplasty is allowed).\n* Absence of coronaplasty or coronaplasty performed \\\u003C 3 months ago or coronaplasty did not leave sufficiently pronounced coronal ridge as defined by the surgeons' expert opinion (This criterion is only obligatory in the epithesis group, not in the prosthesis group)\n* Penile dimensions are not anatomic (e.g. too small or too large).\n* Underlying LUTDs requiring further investigation and\u002For treatment.\n* Inadequate protective sensation in the penis.\n* No established (sexual) partner and\u002For partner is not willing to take part in the study.\n* Patient and\u002For partner have no interest in penetrative sexual intercourse.",{"count":376,"type":22},[25],"Transgender and gender diverse (TGD) individuals most often choose for phalloplasty as a means to create masculine external genitalia. The neophallus created in phalloplasty is usually insufficient for penetrative sexual intercourse due to the lack of erectile structures. Therefore, implantation of an internal erectile prosthesis or use of an external device or epithesis is required.\n\nInternal prostheses are the main method for attaining penile rigidity after phalloplasty, but they carry a high risk of complications. Previous research has shown that up to 22% of prostheses for cisgender men were explanted due to various reasons, including infection, erosion, and malfunction within 20 months. The lack of reliable and durable erectile devices leads to a large proportion of patients either choosing phalloplasty but never going for the placement of an erectile prosthesis or completely abandoning the idea of GGAS under the form of phalloplasty. Secondarily, TGD individuals may be concerned about complication rates and likely need for additional surgeries associated with penile implant surgery. Therefore, alternative options for transgender and gender non-conforming patients after phalloplasty are needed. These alternatives may be surgical or non-surgical.\n\nExternal penile epitheses or penile splints were originally designed for cisgender men with erectile dysfunction but have been used experimentally by post-phalloplasty transgender men. While there is no data on the usability and durability of penile epitheses in a TGD population, they may be a viable alternative to an internal penile prosthesis after phalloplasty. Penile lifters or splints, marketed as ElatorTM or ErektorTM, are commercially available and consist of two rigid rings connected by rigid metal rods. The biggest of two rings is placed around the base of the phallus, and the second ring is placed behind the coronal ridge. By connecting the rods to the ring at the base of the penis, tension and rigidity between the two rings is created, allowing the user to penetrate their partner and remove the device after intercourse.\n\nThe current study aims to extend the knowledge on these external devices by comparing them to the implantation of an internal penile prosthesis in post-phalloplasty transgender patients.",[602,424,603,604,28],[606,607,608,609,610,611,612,613,614,616,615,639],"2024-08-02",{"date":66,"type":33},{"date":662,"type":33},"2023-05-17",{"date":664,"type":22},"2025-12-31",{"name":624,"class":40}]